Vyvanse – Talk Bio

Actionable Insights Powered by AI

Astellas Closes California Facility; Takeda Expands ADHD Drug Production Amid Generic Competition

8 months ago talkbio0Tagged Astellas, Attention deficit hyperactivity disorder, competition, Facility (object), Reparative closure, Takeda, Vyvanse

Astellas, Takeda, ADHD drug, Vyvanse, generic competition, facility closure

Takeda Pharmaceuticals Revises Profit Forecast Due to Vyvanse Patent Expiration, Plans $900M Restructuring by 2024

12 months ago talkbio0Tagged Attention deficit hyperactivity disorder, Expiration, function, Legal patent, profit, restructuring, Takeda, Vyvanse

Takeda Pharmaceuticals, Vyvanse, patent expiration, profit outlook, restructuring, ADHD medication